Clients
Hobson Prior operates a truly international search and placement model having successfully completed over 2000 permanent and interim assignments throughout Europe.
-
To support this we create client-specific candidate talent pools, sourced against the specific experience, skills, cultural and commercial expectations of clients functional and organisational requirements.
-
In building and maintaining these talent pools, our approach combines the traditional sourcing methods of file research, advertising, referral and search, to provide the broadest choice possible for each client with whom we work.
-
Our key talent acquisition tool is targeted headhunting, with over 50% of successfully completed assignments resulting from the consistent application of our proactive search methodology for both permanent and interim instructions.
Key Value Add
Our commitment to exceptional standards of service means that we aim to provide a key value add to each of our clients and to incorporate the following elements into each assignment:
• Candidate Talent Pooling
• Pre-Employment Security Vetting
• Employer Branding Profiles
• Compliance Review & Support
• Management Review & Reporting
• Financial & PO Reporting
• Market Information & Benchmarking
Vacancy Search
Latest News
Anthera listing confirms weak IPO market
The disappointing public outing for Anthera Pharmaceuticals this week, eventually listing on the Nasdaq at a 50% discount to its proposed price, was not an encouraging sign for those US companies with active IPO filings at the SEC who must now be reassessing their next financing steps.
The weakness of Anthera’s IPO – $54m raised was the lowest since Cumberland Pharmaceuticals cracked open the IPO window last August – mirrors the poor performance of Omeros since it went public in October. Anthera and Omeros are both developmental stage, high risk investment opportunities, similar to five of the six companies currently pursuing an IPO. The one mature company on the list, Prometheus Laboratories, with eight marketed products and annual profits since 2005, therefore appears the standout IPO candidate, but only if it clears up uncertainty over rights to its biggest selling product (see tables below).
Investors still risk averse
Anthera was the fifth US pharmaceutical company to go public since the broader stock market recovery in the second half of 2009.
As the table below shows, the initial optimism that IPOs would start to flow has dampened as the two most recent public offerings, Anthera and Ironwood Pharmaceuticals, have only squeezed onto the market at a significant discount to the proposed price. The average discount between the filed price and the actual list price is 20%, even after some companies had already cut back their price targets.
